30 closest matches · ranked by relevance
Cholecystitis
Primary: Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis — 9; 0; 1; 1 Participants
Hyperemesis Gravidarum · Pregnancy Related
Primary: Blood Cholecystokinin (CCK) Levels — 53.13; 54.55; 73.61; 81.24 picogram/mililiters (pg/ml) — p=0.05
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
Pancreaticobiliary Reflux
Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl
Acute Cholecystitis · Empyema of Gallbladder · Abscess of Gallbladder
Primary: Complication — 7; 7 participants
Healthy
Primary: Coefficient of Variation (CV) for Gallbladder Ejection Fraction (GBEF) for Each Infusion Method — 51.66; 62.75; 71.38; 40.46 percentage
Postcholecystectomy Syndrome
Primary: the Number of the Participants Have Postoperative RUQ Pain — 3; 9 number of participants
Cholelithiasis · Ultrasonography · Laparoscopic Gastric Bypass
Primary: Cholelithiasis on Transabdominal Ultrasound Versus Laparoscopic Ultrasound. — 61; 60 participants — p=0.763
Cholecystitis
Primary: Complications Related to ICG — 0; 0 % of Participants with Complications
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
Cholecystitis, Acute
Primary: Number of Days to Resolution of Acute Cholecystitis — 5.30 days
Bile Acid Synthesis Defect · Inborn Error of Bile Acid Metabolism · Inborn Error of Bile Acid Conjugation
Primary: Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation. — 5 Participants
Abdominal Pain
Primary: Gallbladder Ejection Fraction — 15 percentage of ejection of tracer
Diabetes Mellitus, Type 2
Primary: Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect — 47.4352; 38.4331 Percent of…
Gastroesophageal Reflux Disease
Primary: Protection Against DNA Damage by UDCA — 1.068; .82 Relative Densitometry Units
Obesity
Primary: Change in 48h-fecal Bile Acid Excretion (μmol/L) Between Baseline and High Fat Diet — 543; 344 (μmol/L)/48 hour
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
Cholecystitis · Cholelithiasis
Primary: Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light — 64; 157; 159; 243 Participants
Cholelithiasis · Cholecystitis · Pancreatitis Biliary
Primary: Operative Time — 51.6; 44.4 minutes
Cholangiocarcinoma
Primary: The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and…
Cholelithiasis
Primary: Number of Participants With Subhepatic Collection at Ultrasonographic Examination — 45; 46 Participants
Gastroesophageal Reflux Disease · Morbid Obesity
Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
Acute Cholecystitis
Primary: Number of Participants With Infectious Postoperative Complications — 8; 7 Participants
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Irritable Bowel Syndrome With Diarrhea
Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale
Stage II Gallbladder Cancer · Stage IIIA Gallbladder Cancer · Stage IIIB Gallbladder Cancer
Primary: Response Rate According to RECIST Criteria — 3; 0 participants